• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Aiforia's image recognition models also available on the PathPresenter platform

AIFORIAAnalyst Comment24.03.2025 klo 08.25
Antti Luiro, Frans-Mikael Rostedt
Discuss

Translation: Original published in Finnish on 3/21/2025 at 4:53 pm EET.

PathPresenter is developing a workflow system for pathologists that integrates models from multiple image analysis solution providers (such as Aiforia). According to the press release, Aiforia's models will be made widely available on the PathPresenter platform. 

Earlier on Friday, Aiforia announced a very similar partnership with Techcyte, and we detailed the impact of such partnerships on the company's investment story in our comment at the time. These partnerships will, in principle, promote market formation and support the strong revenue growth we forecast for Aiforia, although there are nuances to the matter. Our more detailed commentary on the previous partnership press release can be found here. 

Login required

This content is only available for logged in users

Create account

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more on company page

Key Estimate Figures10.03.2025

202425e26e
Revenue2.94.77.6
growth-%18.9 %65.7 %60.0 %
EBIT (adj.)-12.2-11.9-12.0
EBIT-% (adj.)-427.8 %-252.9 %-158.1 %
EPS (adj.)-0.41-0.36-0.36
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

This video discusses general industry outlooks and events. Aiforia isn’t mentioned specifically, but the company is active in this market and...
21 hours ago
by Salvelinus
9
In my opinion, the financing news was much better than I expected. I was certainly expecting a directed share issue, which would have been frustrating...
6/17/2026, 7:21 AM
by JusaVaan
24
nuways-ag.com NuWays Platform
6/17/2026, 6:28 AM
by Salvelinus
10
ecdp2026.org European Society of Digital and Integrative Pathology | ECDP2026 | 22nd... Today marks the start of a congress where Aiforia is...
6/17/2026, 5:44 AM
by Salvelinus
16
These types of bridge financing arrangements are quite common nowadays. It also indicates that the company genuinely believes cash flow positivity...
6/16/2026, 4:01 PM
25
Usually a company can and should raise debt only when the stock and cash flows are strong enough, this is kind of the opposite situation
6/16/2026, 1:53 PM
by Bullbear
1
Yeah, even if the loan eliminates the acute financing risk, we will likely see at least one more share issue. It is also possible that the potential...
6/16/2026, 9:49 AM
6